| Literature DB >> 27773962 |
Stephanie Seneff1, Nancy L Swanson2, Gerald Koenig3, Chen Li1.
Abstract
Osteonecrosis of the jaw (ONJ), a rare side effect of bisphosphonate therapy, is a debilitating disorder with a poorly understood etiology. FDA's Adverse Event Reporting System (FAERS) provides the opportunity to investigate this disease. Our goals were to analyze FAERS data to discover possible relationships between ONJ and specific conditions and drugs and then to consult the scientific literature to deduce biological explanations. Our methodology revealed a very strong association between gastroesophageal reflux and bisphosphonate-induced ONJ, suggesting acidosis as a key factor. Overgrowth of acidophilic species, particularly Streptococcus mutans, in the oral microbiome in the context of insufficient acid buffering due to impaired salivary glands maintains the low pH that sustains damage to the mucosa. Significant associations between ONJ and adrenal insufficiency, vitamin C deficiency, and Sjögren's syndrome were found. Glucose 6 phosphate dehydrogenase (G6PD) deficiency can explain much of the pathology. An inability to maintain vitamin C and other antioxidants in the reduced form leads to vascular oxidative damage and impaired adrenal function. Thus, pathogen-induced acidosis, hypoxia, and insufficient antioxidant defenses together induce ONJ. G6PD deficiency and adrenal insufficiency are underlying factors. Impaired supply of adrenal-derived sulfated sterols such as DHEA sulfate may drive the disease process.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27773962 PMCID: PMC5059643 DOI: 10.1155/2016/8376979
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Evidence that ONJ is associated with a very strong overrepresentation of diseases of the teeth and gums, as well as rhinitis, compared to NOT ONJ.
| Side effect | Count 1 | Count 2 |
| Score |
|---|---|---|---|---|
| % periodont | 1950 | 2081 | 65.7 | 985 |
| % dental | 4281 | 9029 | 33.5 | 971 |
| Tooth extraction | 1615 | 5325 | 21.7 | 956 |
| % rhinitis | 703 | 3121 | 15.9 | 941 |
| % mucosa | 1002 | 5085 | 14.2 | 934 |
| Total count | 10580 | 762002 | 1.0 | 500 |
Evidence that ONJ is associated with vitamin C deficiency. The symptoms associated with scurvy as defined in [33] are all significantly overrepresented (>95% CI) in association with ONJ compared to NOT ONJ, many by a wide margin.
| Side effect | Count 1 | Count 2 |
| Score |
|---|---|---|---|---|
| Bleeding gums | 841 | 1792 | 33.5 | 971 |
| Impaired wound healing | 304 | 716 | 30.3 | 968 |
| Hyperkeratosis | 274 | 925 | 21.2 | 955 |
| Joint effusions | 401 | 1742 | 16.5 | 943 |
| Inflamed gums | 458 | 2231 | 14.6 | 936 |
| Sjögren's | 85 | 531 | 11.5 | 920 |
| Ecchymosis | 226 | 1437 | 11.2 | 918 |
| Infection | 15953 | 122729 | 9.3 | 903 |
| Folliculitis | 73 | 582 | 9.0 | 900 |
| Dry eye | 331 | 2796 | 8.5 | 895 |
| Dry mouth | 608 | 7289 | 6.0 | 857 |
| Petechiae | 63 | 1125 | 4.0 | 801 |
| Muscular weakness | 734 | 13614 | 3.9 | 795 |
| Anaemia | 4602 | 86759 | 3.8 | 792 |
| Haemorrhage | 2996 | 62389 | 3.4 | 775 |
| Fatigue | 2653 | 62014 | 3.1 | 754 |
| Myalgia | 1215 | 30573 | 2.9 | 741 |
| Arthralgia | 3012 | 78226 | 2.8 | 734 |
| Depression | 3292 | 106774 | 2.2 | 689 |
| Total count | 10580 | 762002 | 1.0 | 500 |
Evidence that ONJ is linked to Sjögren's syndrome. Both the syndrome itself and the various conditions associated with the syndrome are all overrepresented in association with ONJ compared to NOT ONJ, some by a wide margin of significance.
| Side effect | Count 1 | Count 2 |
| Score |
|---|---|---|---|---|
| Sialoadenitis | 103 | 209 | 34.7 | 972 |
| Vulvovaginal dryness | 121 | 444 | 19.4 | 951 |
| % Sjögren's | 85 | 531 | 11.5 | 920 |
| Dry eye | 331 | 2796 | 8.5 | 895 |
| % lymphoma | 196 | 2289 | 6.1 | 860 |
| Dry mouth | 608 | 7289 | 6.0 | 857 |
| Dry skin | 129 | 5290 | 1.8 | 637 |
| Total count | 10580 | 762002 | 1.0 | 500 |
Distribution of the main drugs assigned as plausibly causative in the ONJ subset.
| Drug class | Count | Percent |
|---|---|---|
| Bisphosphonates | 6153 | 58.1% |
| N-containing IV bisphosphonates | 4206 | 39.8% |
| Other bone resorption inhibitors | 89 | 0.8% |
| Other drugs | 132 | 1.2% |
|
| ||
| Total | 10580 | 100% |
Evidence that ONJ is associated with features strongly linked to osteoporosis. Despite small counts in some cases, all of these features are significantly overrepresented (>95% CI) in association with ONJ compared to NOT ONJ, by a wide margin.
| Side effect | Count 1 | Count 2 |
| Score |
|---|---|---|---|---|
| Kyphosis | 550 | 702 | 54.6 | 982 |
| Postmenopause | 30 | 70 | 30.3 | 968 |
| Spinal compression fracture | 718 | 1764 | 29.3 | 967 |
| Spinal cord compression | 208 | 587 | 25.3 | 962 |
| % fracture | 11303 | 48430 | 16.5 | 943 |
| Obesity | 427 | 2080 | 14.6 | 936 |
| Type 2 diabetes mellitus | 393 | 2269 | 12.3 | 925 |
| Menopause | 75 | 554 | 9.6 | 906 |
| Diabetes mellitus | 666 | 7614 | 6.3 | 863 |
Evidence that ONJ is linked to adrenal insufficiency. Not only is adrenal insufficiency itself highly overrepresented in association with ONJ compared to NOT ONJ, but also the various symptoms associated with adrenal insufficiency are also unusually common among sufferers of ONJ. The score is defined in (1).
| Side effect | Count 1 | Count 2 |
| Score |
|---|---|---|---|---|
| Any adrenal | 591 | 1541 | 27.6 | 965 |
| Addison's disease | 35 | 101 | 24.6 | 961 |
| Adrenal insufficiency | 133 | 561 | 16.9 | 944 |
| Orthostatic hypotension | 216 | 1592 | 9.8 | 907 |
| Myopathy | 628 | 5168 | 8.7 | 897 |
| Vertigo | 647 | 6526 | 7.1 | 877 |
| Hypoglycaemia | 225 | 2930 | 5.5 | 846 |
| Muscular weakness | 734 | 13614 | 3.9 | 795 |
| Diarrhea | 2265 | 48901 | 3.3 | 769 |
| Fatigue | 2653 | 62014 | 3.1 | 754 |
| Vomiting | 1594 | 48934 | 2.3 | 701 |
| Nausea | 2186 | 74796 | 2.1 | 677 |
| Disorientation | 107 | 4606 | 1.7 | 625 |
The set of symptom classes that were overrepresented by at least a factor of 3 in the B AND G group compared to the predicted occurrence based on the B NOT G group and the G NOT B group. B: bisphosphonates; G: GERD. As indicated, “MUCOSA” was a substring match, and everything else required exact match. Computation of the score is defined in (1) and computation of the bias is defined in (2).
| Side effect |
|
|
| Bias |
|---|---|---|---|---|
| Osteonecrosis of jaw | 905 | 15 | 966 | 195.85 |
| Bone marrow oedema | 858 | 204 | 943 | 10.68 |
| Anhedonia | 660 | 428 | 851 | 3.93 |
| % mucosa | 738 | 595 | 941 | 3.85 |
| Sialoadenitis | 884 | 395 | 949 | 3.74 |
| Lymphoedema | 809 | 546 | 950 | 3.73 |
| Oedema | 633 | 675 | 915 | 3.00 |
List of drug classes that were overrepresented at least fourfold in the B AND G group compared to what is predicted based on the B-only and G-only groups. The ratio was computed according to (2) in the text. B: bisphosphonates; G: GERD.
| Side effect |
|
|
| Bias |
|---|---|---|---|---|
| Estrogen receptor antagonists | 887 | 50 | 960 | 58.09 |
| Mouth and throat products | 889 | 178 | 971 | 19.31 |
| General anesthetic | 614 | 442 | 921 | 9.25 |
| Mineralocorticoids | 697 | 488 | 951 | 8.85 |
| Tamiflu | 237 | 474 | 695 | 8.14 |
| Thalidomide derivatives | 806 | 230 | 900 | 7.25 |
| Radiation therapy | 855 | 271 | 937 | 6.79 |
| Transfusion | 539 | 268 | 743 | 6.75 |
| Aminoglycoside antibiotics | 554 | 408 | 841 | 6.18 |
| Other immunosuppressants | 711 | 286 | 851 | 5.80 |
| Opium receptor antagonists | 687 | 525 | 928 | 5.31 |
| Unspecified hormones | 861 | 359 | 946 | 5.05 |
| Gonadotropin-releasing hormone | 818 | 200 | 846 | 4.89 |
| Proteasome inhibitors | 792 | 298 | 882 | 4.62 |
| VEGF/VEGFR inhibitors | 612 | 359 | 803 | 4.61 |
| Glycopeptide antibiotics | 600 | 486 | 866 | 4.56 |
| Aromatase inhibitors | 849 | 307 | 915 | 4.32 |
| Smoking cessation agents | 203 | 329 | 356 | 4.43 |
| Antineoplastic antibiotics | 729 | 420 | 896 | 4.42 |
| Recombinant human erythropoietin | 753 | 391 | 889 | 4.09 |
| Antiviral combinations | 170 | 453 | 408 | 4.06 |
Overrepresentation in ONJ of cancers typically treated with many of the drugs that were found to be overrepresented in the B AND G group, when compared to NOT ONJ. All of these results are significant at the 95% CI level by a wide margin. B: bisphosphonates; G: GERD.
| Side effect | Count 1 | Count 2 |
| Score |
|---|---|---|---|---|
| Myeloma recurrence | 141 | 62 | 141.9 | 993 |
| Breast cancer recurrent | 155 | 187 | 57.8 | 983 |
| Prostate cancer metastatic | 144 | 185 | 54.6 | 982 |
| Multiple myeloma | 905 | 1404 | 44.5 | 978 |
| Prostate cancer | 164 | 818 | 14.4 | 935 |
| Breast cancer metastatic | 263 | 552 | 33.5 | 971 |
| Breast cancer | 234 | 2311 | 7.3 | 879 |
Figure 1Schematic of the sequential stages of the proposed disease process leading to ONJ and the subsequent protection from IBD due to associated erosion of the oral mucosa.
Figure 2Schematic of complex structure of heparan sulfate chains. [X], [Y], and [Z] can each be just a hydrogen atom or an acetyl group or a sulfate in a complex information-bearing pattern.